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Introduction: Amiodarone is a highly effective antiarrhythmic-drug with well recognized toxic side-
effects. The effects of the drug late in patients with atrial fibrillation (AF) is not well described.
Methods and results: We present a single centre prospectively collected series of patients with thyro-
toxicosis occurring late after the cessation of amiodarone. Between 2006 and 2018, 8 patients were
identified with amiodarone induced thyrotoxicosis (AIT). Amiodarone was prescribed for AF in 7 patients
and ventricular tachycardia in 1 patient. Mean duration of therapy was 329 [42e1092] days, mean dose
of 200 ± 103.5 mg/day. Amiodarone use was short term (<140 days) in 4 of the 8 cases, with one treated
for 42 days. Patients presented with symptoms including weight loss, tremors, palpitations, AF, sweats all
indicative of AIT at a median of 347 [60e967] days post cessation. Thyroid function testing confirmed
suppressed thyroid stimulating hormone and elevated T levels in all patients. Nuclear thyroid imaging in
all cases demonstrated low uptake of iodine indicative of Type II AIT. All patients recovered following
pharmaceutical treatment with Carbimazole and Prednisolone.
Conclusions: We describe a series of patients with late thyrotoxicosis after exposure to amiodarone. Our
findings highlight the need for a high-index of clinical suspicion for AIT regardless of treatment duration
or time after cessation of amiodarone.
Copyright © 2020, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Amiodarone is a highly effective antiarrhythmic drug commonly
used in the treatment of ventricular arrhythmias and atrial fibril-
lation (AF). However, the toxicity of amiodarone is extensive with a
myriad of potential organ damage including the liver, lungs, cornea,
skin, and thyroid gland. Specifically, these adverse effects have been
shown to occur at various time points during amiodarone use with
thyroid dysfunction seen in 15e20% of patients treated [1].
Furthermore, several isolated cases of thyroid dysfunction have
been reported to occur following cessation of amiodarone [2,3].
Here, we present a single centre case series of 8 patients with
amiodarone induced thyrotoxicosis (AIT) occurring late following
ceasing the drug.stract award e Allied profes-
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This is a single centre case series of amiodarone induced
thyrotoxicosis were prospectively collected between 1st January
2006 and 30th June 2018. Over this time period those who were
prescribed amiodarone were followed to assess complications that
may arise. Any patient who presented with symptoms of thyro-
toxicosis as a result from exposurewith Amiodaronewere collected
and included for analysis. Upon diagnosis, all patients were referred
to an endocrinologist for treatment and management with data
from this collected. All patients underwent thyroid function testing,
and nuclear thyroid imaging. Baseline datawas collected and follow
up of the patients was undertaken to assess complications, man-
agement and progress. This case series was approved by the insti-
tutional Human Research Ethics Committee.
3. Results
In this single centre cohort a total of 386 patients were pre-
scribed amiodarone of which 8 (2.1%) presented with amiodarone
induced thyrotoxicosis. The 8 patients comprised of 3 females and 5Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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amiodarone therapy for AF (n ¼ 7) and ventricular tachycardia
(n ¼ 1). Median duration of amiodarone therapy was 329
[42e1092] days at a mean dose of 200 ± 103.5 mg per day. Of note,
amiodarone use was only short term (<140 days) in 4 of the 8 cases,
with one treated for only 42 days. All patients presented with
symptoms indicative of thyrotoxicosis or symptomatic AF at a
median of 347 [60e967] days post cessation of amiodarone. The
three patients with symptomatic AF had previously undergone
successful catheter ablation for AF with no arrhythmia recurrence
until their presentation with thyrotoxicosis. The longest temporal
gap between cessation of amiodarone and onset of thyrotoxicosis
was almost 3 years. All patients underwent thyroid function testing
with evidence of suppressed thyroid stimulating hormone (TSH)
and elevated T3, and T4 levels (Table 1). Nuclear thyroid imaging in
all 8 cases demonstrated low uptake of iodine in the thyroid gland
indicative of Type II AIT (Fig. 1). One patient underwent thyroid
doppler scan which demonstrated coarsened thyroid echotexture
with normal vasculature. All patients were referred to an endocri-
nologist for furthermanagement. Patients weremanaged as per the
guidelines [4] and were successfully treated with a combination of
prednisolone and carbimazole; with 3 patients requiring long-term
carbimazole, 1 patient required propylthiouracil following reaction
to carbimazole. Notably, the three patients with recurrent AF
became free from arrhythmia following achievement of euthyroid
status. Here, we detailed two cases from our series.
The first case is a 54-year-old male with longstanding persistent
AF and a previous history of hypertension and thromboembolic
stroke. He was treated with 53 weeks of amiodarone prior to un-
dergoing catheter ablation for AF. However, 349 days after having
ceased amiodarone, he presented with classic symptoms of sweats,
weight loss, diarrhoea, and poor sleep. His elevated thyroid hor-
mone profile (Table 1, Patient 1) and low uptake of iodine from
nuclear imaging confirmed the diagnosis of Type II AIT. He
responded well to prednisolone and carbimazole therapy, his
symptoms resolved, and he had complete normalisation of thyroid
hormone profile.
The second case is a 45-year-old male initially presented withTable 1
Patient characteristics.









1 54 M AF 200 53 349
2 67 F AF 200 20 329
3 45 M VT 400 12 967
4 72 F AF 400 6 175
5 71 F AF 400 12 180
6 68 M AF 200 156 60
7 58 F AF 200 53 249
8 55 M AF 200 78 469
Mean 67 ± 10 e e 200 ± 103.5 47 [6e156] 347 [60e967]
M  male; F e female; AF e atrial fibrillation; VT e ventricular tachycardia.rapid ventricular flutter andwas diagnosedwith cardiac sarcoidosis
with pulmonary involvement. He received an implantable
cardioverter-defibrillator. Subsequently, he presented with ven-
tricular tachycardia storm resulting in multiple shocks from his
device. He was then commenced on a short course of amiodarone
as a bridge to catheter ablation therapy. Interestingly, despite a
relatively short exposure to amiodarone for only 12 weeks, he
developed typical symptoms of thyrotoxicosis consisting of
tremors, palpitations, sweats, bloating and a choking sensation at
967 days after cessation of therapy. Thyroid function testing
(Table 1, Patient 3) and nuclear thyroid scanwere indicative of Type
II AIT. He was successfully treated with prednisolone and carbi-
mazole and became euthyroid within 3 months, his symptoms
improved.
All Patients were managed as per the guidelines and were
successfully treated with a combination of prednisolone and car-
bimazole; with 3 patients requiring long-term carbimazole, 1 pa-
tient required propylthiouracil following reaction to carbimazole.
The three patients with recurrent AF became free from arrhythmia
following achievement of euthyroid status. No patients developed
hypothyroidism following this.4. Discussion
This case series highlight the extent of the thyroid toxicity of
amiodarone whereby late-onset Type II AIT can occur long after
therapy cessation and evenwith short-term usage. Amiodarone has
a complex chemical structure with each molecule having 2 iodine
atoms constituting 37% of its total mass [5,6]. It is estimated that
10% of the iodine content is released as free iodine into the circu-
lation, equating to a significant load of 100e300 times of its rec-
ommended daily iodine intake [5e7]. Amiodarone is distributed
amongst a variety of tissues including the adipose tissue, myocar-
dium, liver, and lung. It has a very long half-life of up to 100 days,
due predominantly to its storage in adipose tissue.
There are two known types of AIT. Type I AIT is due to an excess
of iodine that results in the greater production of thyroid hormones















22.2 8.6 <0.01 Symptomatic AF Carbimazole,
Prednisolone
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Fig. 1. NUCLEAR THYROID SCAN
Left: Normal thyroid scan with homogeneous and normal uptake of the radioactive iodine tracer (0.81%) in all parts of the thyroid gland in a healthy patient. Right: Globally reduced
uptake of the radioactive iodine tracer (0.14%) in all parts of the thyroid gland in one of the patients with amiodarone induced thyrotoxicosis. (Different views: anterior, right
anterior oblique (RAO), left anterior oblique (LAO)).
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flow can be seen with Doppler sonography and increased radio-
nucleotide uptake of iodine with nuclear scan [9]. By contrast, Type
II AIT often occurs in patients with a normal thyroid [2,5,6,8] and
represents a destructive thyroiditis that releases pre-formed thy-
roid hormones due to local inflammation. Here, thyroid imaging
will show decreased blood flow and low radionucleotide uptake of
iodine. This inflammatory condition is highly responsive to steroid
and thyroid suppressive therapies. Amiodarone toxicity has been
reported previously in patients while on active amiodarone therapy
[2,6,10], in the current series however, we reported 8 cases of late-
onset Type II AIT following cessation of amiodarone. Other thyroid
toxicities such as amiodarone induced hypothyroidism and Type I
AIT have been described both during active amiodarone use and
months after its cessation [3,7]. Specifically, only a few isolated
cases of AIT have been described late following the cessation of
amiodarone although these cases appear to be mixed AIT and not
classically Type II AIT [11,12].
4.1. Clinical implications
Guidelines from more than a decade ago suggest thyroid
screening for patients receiving amiodarone at baseline and 6-
monthly thereafter with no recommendations for surveillance post
drug cessation [13]. Our case series suggest that extended thyroid
screening may be needed in conjunction with ongoing clinical
vigilance for AIT in patients with previous exposure to amiodarone.
5. Conclusions
Delayed presentation of thyroid disorders in patients with pre-
vious exposure to amiodaronemay not be uncommon. Our findings
highlight the need for a high index of clinical suspicion for AIT
regardless of treatment duration.
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